These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15635885)

  • 1. [Oral administration of iron with vitamin C in haemodialyzed patients].
    Derzsiová K; Mydlík M; Boldizsár J; Hríbiková M; Petrovicová J
    Vnitr Lek; 2001 Apr; 47(4):210-4. PubMed ID: 15635885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral use of iron with vitamin C in hemodialyzed patients.
    Mydlík M; Derzsiová K; Boldizsár J; Hríbiková M; Petrovicová J
    J Ren Nutr; 2003 Jan; 13(1):47-51. PubMed ID: 12563623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of iron deficiency on the development of anemia in patients on regular dialysis therapy].
    Zadrazil J; Papajík T; Bachleda P; Budíková M; Novotný D; Scudla V
    Vnitr Lek; 1994 Jun; 40(6):362-6. PubMed ID: 8073646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oxalic acid--important uremic toxin].
    Mydlík M; Derzsiová K
    Vnitr Lek; 2010 Jul; 56(7):695-701. PubMed ID: 20842915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The iron reserve status in patients on regular dialysis treatment].
    Zadrazil J; Papajík T; Scudla V; Jezáková J; Budíková M; Slavícek J
    Vnitr Lek; 1991 Apr; 37(4):369-75. PubMed ID: 2053308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients.
    Chan D; Irish A; Dogra G
    Nephrology (Carlton); 2005 Aug; 10(4):336-40. PubMed ID: 16109077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of lowering plasma homocysteine levels on some parameters of thrombotic activity in haemodialyzed patients with chronic renal failure].
    Kozłowska I
    Ann Acad Med Stetin; 2004; 50(1):87-95. PubMed ID: 16871747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
    Sirover WD; Siddiqui AA; Benz RL
    Ren Fail; 2008; 30(9):884-9. PubMed ID: 18925528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron absorption and therapy after gastric bypass.
    Rhode BM; Shustik C; Christou NV; MacLean LD
    Obes Surg; 1999 Feb; 9(1):17-21. PubMed ID: 10065575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience in the treatment of iron deficiency anemia with ferro-folgamma].
    Nikitin EN; Krasnoperova OV; Nikitin IuE
    Klin Med (Mosk); 2009; 87(3):64-7. PubMed ID: 19469261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.